The life science and biotech PR distribution service

ProteoNic Unveils Early Access Program, Elevating Viral Vector Titers with Transformative LV-2G UNic® Technology

ProteoNic Logo v2

LEIDEN, the Netherlands, March 27, 2024 / Biotech Newswire / -- ProteoNic Biosciences, a leading provider of premium vector technology and services for the production of biologics, is announcing the launch of its highly anticipated LV-2G UNic® Early Access Program. This program marks a significant milestone in lentivirus manufacturing optimization, offering access to groundbreaking vector technology designed to revolutionize viral vector production.

With the official launch on March 20, 2024, ProteoNic extends a warm invitation to CDMOs, biotechs, and biopharmaceutical companies to experience firsthand the transformative potential of LV-2G UNic®. By seamlessly integrating this cutting-edge vector technology into existing systems, participants can achieve remarkable enhancements in titers, paving the way for increased viral vector production capacity and substantial improvements in manufacturing cost efficiency.

Frank Pieper, CEO of ProteoNic, shared his excitement about the program's potential impact, stating, "The LV-2G UNic® Early Access Program will serve as a launching platform for our viral vector manufacturing innovation. By offering early access to our state-of-the-art vector technology, we empower researchers to unlock unprecedented levels of efficiency and productivity in viral vector manufacturing."

LV-2G UNic® represents next generation vector technology, engineered to elevate lentiviral titers across a wide array of expression systems. The technology drives enhanced infectious viral particle production, by providing a significant boost in gRNA production through increased transcription levels achieved with ProteoNic’s patented Dual Promoter system.

Participation in the LV-2G UNic® Early Access Program offers exclusive benefits, including access to ProteoNic’s cutting-edge LV-2G UNic® vector technology, optimizing lentiviral particle expression and co-development opportunities. This technology can be seamlessly integrated into current workflows with minimal to no process development required.

For more information about LV-2G UNic® and the Early Access Program, visit proteonic.nl


For high resoution please click the image.


About ProteoNic BV
ProteoNic is a privately held company with offices in Leiden, the Netherlands and in the Boston area, USA. The company offers technology and services for the generation of cell lines and viral vectors with greatly improved production characteristics. The company commercializes its proprietary 2G UNic® technology through licensing and partnership arrangements.



ProteoNic BV
Jonathan Frampton, PhD
Director, Business Development
+44 7961 144115
This email address is being protected from spambots. You need JavaScript enabled to view it.


Keywords: Manufacturing Industry; Genetic Vectors; Genetic Therapy; Cell- and Tissue-Based Therapy; Regenerative Medicine; Biological Products; Industry; Biotechnology; Technology; Lentivirus; Genetic Therapy; Cell Line Development; Cell Proliferation; Cells, Cultured; Netherlands; ProteoNic Biosciences; Vector technology; Biologics; LV-2G UNic®; Early Access Program; Lentivirus manufacturing; CDMOs; Biotechs; Biopharmaceutical companies; Titer enhancement; Viral vector production; Manufacturing cost efficiency; Frank Pieper; Infectious viral particle production; gRNA production; Dual Promoter system; Cell lines; Leiden, Netherlands; Boston, USA; Licensing; Partnership arrangements

Published by Biotech Newswire

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.